Ljiljana Stamatovic

Belgrade, SE, Serbia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.

Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study.

Journal: Clinical breast cancer

Published: April 01, 2025

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Journal: The New England journal of medicine

Published: January 15, 2025

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 05, 2021

Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.

Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.

Journal: Cancer

Published: January 02, 2020

The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.

The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: December 21, 2018

Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.

Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 26, 2018

Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE.

Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: May 11, 2018

Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.

Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.

Journal: Familial cancer

Published: July 08, 2017

Polymorphic expression of glutathione transferases A1, M1, P1 and T1 in epithelial ovarian cancer: a Serbian case-control study.

Polymorphic expression of glutathione transferases A1, M1, P1 and T1 in epithelial ovarian cancer: a Serbian case-control study.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: April 03, 2017

Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia.

Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia.

Journal: Psycho-oncology

Published: January 12, 2017

Delays in diagnosis and treatment of breast cancer: a multinational analysis.

Delays in diagnosis and treatment of breast cancer: a multinational analysis.

Journal: European journal of public health

Published: September 14, 2013

Change of influence of prognostic markers on metastasis free interval during and after adjuvant tamoxifen therapy in breast cancer patients.

Change of influence of prognostic markers on metastasis free interval during and after adjuvant tamoxifen therapy in breast cancer patients.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: July 03, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026